GLYC News and Press, GlycoMimetics Inc. From 10/26/21

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its third quarter financial results on Tuesday, November 2, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and ...

Manuscript highlights MRD negative rate of 69% in the relapsed/refractory patient population Efficacy and safety data from a Phase 1/2 clinical study of uproleselan, GlycoMimetics’ lead investigational drug, were published online September 16, 2021 in the journal BL...

RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborate to de...

GlycoMimetics, Inc. (GLYC) Q2 2021 Earnings Conference Call August 5, 2021, 8:30 AM ET Company Participants Shari Annes - Investor Relations Rachel King - Chief Executive Officer Eric Feldman - Senior Vice President and Chief Medical Officer Brian Hahn - Senior Vice President and Chief Financ...

Image source: The Motley Fool. GlycoMimetics, inc (NASDAQ: GLYC) Q2 2021 Earnings Call Aug 6, 2021 , 2:00 p.m. ET Operator Continue reading For further details see: GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript

The following slide deck was published by GlycoMimetics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: GlycoMimetics, Inc. 2021 Q2 - Results - Earnings Call Presentation

GlycoMimetics (NASDAQ:GLYC): Q2 GAAP EPS of -$0.28 beats by $0.03. Cash and cash equivalents of $118.9M Press Release For further details see: GlycoMimetics EPS beats by $0.03

Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Completion of enrollment is expected by year-end 2021 for the Phase 2 portion of the...

GlycoMimetics (NASDAQ:GLYC) announces the appointment of Harout Semerjian as the company's chief executive officer. Semerjian will succeed retiring founding CEO of the company Rachel King. He is a seasoned executive with strong oncology commercialization experience, will lead t...

Mrs. King, the company’s founding CEO, will remain a Director and advisor to support transition GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to...